Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Total Debt (2016 - 2025)

Pediatrix Medical (MD) has disclosed Total Debt for 17 consecutive years, with $597.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Debt fell 3.29% to $597.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $597.3 million, a 3.29% decrease, with the full-year FY2025 number at $597.3 million, down 3.29% from a year prior.
  • Total Debt was $597.3 million for Q4 2025 at Pediatrix Medical, down from $602.5 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $1.0 billion in Q4 2021 to a low of $55.9 million in Q2 2023.
  • A 5-year average of $622.4 million and a median of $630.1 million in 2024 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: plummeted 91.46% in 2023, then skyrocketed 1027.29% in 2024.
  • Pediatrix Medical's Total Debt stood at $1.0 billion in 2021, then crashed by 35.58% to $647.3 million in 2022, then dropped by 2.15% to $633.3 million in 2023, then dropped by 2.47% to $617.7 million in 2024, then dropped by 3.29% to $597.3 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Total Debt are $597.3 million (Q4 2025), $602.5 million (Q3 2025), and $607.5 million (Q2 2025).